News
CYCC
1.750
+6.06%
0.100
Weekly Report: what happened at CYCC last week (0610-0614)?
Weekly Report · 5d ago
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Avidity Biosciences (NASDAQ:RNA) shares rose 24.5% to $36.0 during Wednesday's pre-market session. Molecular Partners shares moved upwards by 18.43% during the day. The company's market cap stands at $3.4 billion.
Benzinga · 06/12 12:06
Weekly Report: what happened at CYCC last week (0603-0607)?
Weekly Report · 06/10 10:46
12 Health Care Stocks Moving In Thursday's After-Market Session
Venus Concept (NASDAQ:VERO) stock rose 131.0% to $1.43 during Thursday's after-market session. Cyclacel Pharmaceuticals shares increased by 8.58% and Rallybio shares rose 4.69% during the same period. Losers Biomea Fusion and Bright Green stock fell 61.9% and 13.49% respectively.
Benzinga · 06/06 20:31
All You Need to Know About Cyclacel Pharmaceuticals (CYCC) Rating Upgrade to Buy
NASDAQ · 06/06 16:00
Cyclacel's Fadraciclib Reports Efficacy In Patient-Derived Colorectal Cancer Models At The 2024 ASCO Annual Meeting
- Novel CDK2/9 inhibitor fadraciclib induces anaphase catastrophe, a novel cancer-specific mechanism of action. The data were presented at a poster at the American Society of Clinical Oncology Annual Meeting. Cyclacel Pharmaceuticals is developing a novel treatment for metastatic colorectal cancer.
Benzinga · 06/04 12:27
CYCLACEL PHARMACEUTICALS: FADRACICLIB DEMONSTRATES EFFICACY IN PATIENT-DERIVED COLORECTAL CANCER MODELS AT 2024 ASCO ANNUAL MEETING
Reuters · 06/04 12:06
Analysts Are Bullish on Top Healthcare Stocks: Cytokinetics (CYTK), Perspective Therapeutics (CATX)
TipRanks · 06/04 11:50
Cyclacel Pharmaceuticals To Present Clinical Data At 2024 ASCO Annual Meeting Highlighting Oral Fadraciclib's Potential As A Precision Medicine For Cancer
Clinical, PK and PD data from novel CDK2/9 inhibitor fadraciclib monotherapy studies support ongoing proof of concept study in patients with solid tumors and lymphoma. Data presented at a poster at the American Society of Clinical Oncology Annual Meeting.
Benzinga · 06/03 12:38
Weekly Report: what happened at CYCC last week (0527-0531)?
Weekly Report · 06/03 10:48
Weekly Report: what happened at CYCC last week (0520-0524)?
Weekly Report · 05/27 10:52
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers Sharps Technology (NASDAQ:STSS) shares rose to $ during Friday's after-market session. Cyclacel Pharmaceuticals and Adial Pharmaceuticals also moved upwards. Losers DIH Holding US and 60 Degrees stock fell during the session.
Benzinga · 05/24 20:31
Weekly Report: what happened at CYCC last week (0513-0517)?
Weekly Report · 05/20 10:47
CYCC Stock Earnings: Cyclacel Pharmaceuticals Beats EPS for Q1 2024
Investorplace · 05/15 00:54
Cyclacel Pharmaceuticals, Inc. Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the Quarterly Period Ended March 31, 2024
Press release · 05/14 23:41
Cyclacel Pharma: Quarterly report
Press release · 05/14 22:33
Cyclacel Pharmaceuticals GAAP EPS of -$2.27 beats by $2.48
Seeking Alpha · 05/14 20:53
Cyclacel Pharmaceuticals Q1 EPS $(2.27) Beats $(4.74) Estimate, Sales $29.00K
Benzinga · 05/14 20:24
APP, MGNX and CYCC among pre-market losers
On the Move APP, MGNX and CYCC among pre-market losers. Augmedix (AUGX) -38% reports Q1 results. Inotiv (NOTV) will report fiscal 2024 second quarter financial results on May 15, 2024.
Seeking Alpha · 05/14 12:25
Notable earnings after Tuesday's close
Major earnings expected after the bell on Tuesday include: Oxford Lane Capital Corp. And Seadrill Limited. Other major earnings slated for release after Tuesday's close include: Canoo and Canoo. The full earnings season calendar can be found at Seeking Alpha's Earnings season calendar.
Seeking Alpha · 05/13 21:35
More
Webull provides a variety of real-time CYCC stock news. You can receive the latest news about Cyclacel Pharma through multiple platforms. This information may help you make smarter investment decisions.
About CYCC
Cyclacel Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing cancer medicines based on cell cycle, transcriptional regulation and mitosis control biology. The transcriptional regulation program is evaluating fadraciclib, a Cyclin-dependent kinase 9 (CDK9) inhibitor, in solid tumors and hematological malignancies. The epigenetic/anti-mitotic program is evaluating plogosertib, in solid tumors and hematological malignancies. The Company's Plogosertib is a novel, small molecule, selective and potent Polo-like kinase 1 (PLK1) inhibitor, which has demonstrated potent and selective target inhibition (PLK1 IC50 approximately 3 nM) and efficacy in human tumor xenografts at non-toxic doses. Its translational biology program supports the development of plogosertib in solid tumor and hematological malignancy indications.